
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
SEC-MALS characterizes PEGylated proteins to determine the protein-PEG ratio and the molar masses of the constituent protein and PEG at each eluting fraction.







